Cargando…

A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer’s Disease Conversion in Mild Cognitive Impairment

OBJECTIVE: Baseline amyloid burden in mild cognitive impairment (MCI) has been linked to conversion to Alzheimer’s disease (AD), but the comparison of baseline and longitudinal changes in amyloid burden for predicting AD remains unresolved. The objectives of this study aimed to compare the prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choo, IL Han, Chong, Ari, Chung, Ji Yeon, Ha, Jung-Min, Choi, Yu Yong, Kim, Hoowon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136525/ https://www.ncbi.nlm.nih.gov/pubmed/35620825 http://dx.doi.org/10.30773/pi.2022.0014

Ejemplares similares

Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis
por: Seo, Eun Hyun, et al.
Publicado: (2017)

Follow-Up of Brain Single-Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI) in a Case of Seizure Caused by Osmotic Demyelination Syndrome
por: Chong, Ari, et al.
Publicado: (2020)

Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment
por: Lee, Young-Sil, et al.
Publicado: (2021)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
por: Maschio, Cinzia, et al.
Publicado: (2022)

Pre-Mild Cognitive Impairment: Can Visual Memory Predict Who Rapidly Convert to Mild Cognitive Impairment?
por: Seo, Eun Hyun, et al.
Publicado: (2018)

Detection of amyloid in Alzheimer’s disease with positron emission tomography using [(11)C]AZD2184
por: Nyberg, Svante, et al.
Publicado: (2009)

Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains
por: McLean, Daniel, et al.
Publicado: (2012)

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
por: Tian, Mei, et al.
Publicado: (2022)

Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [(18)F]AV-45 Positron Emission Tomography in Chinese Population
por: Huang, Kuo-Lun, et al.
Publicado: (2013)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Statistical Parametric Mapping in Amyloid Positron Emission Tomography
por: Smith, Natasha M., et al.
Publicado: (2022)

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2019)

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
por: Lin, Szu-Ying, et al.
Publicado: (2019)

Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography
por: Risacher, Shannon L., et al.
Publicado: (2017)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

Pathobiolgy and Management of Alzheimer's Disease
por: Kim, Hoowon, et al.
Publicado: (2021)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2020)

Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer’s dementia: a comparison of methods
por: Sörensen, Arnd, et al.
Publicado: (2020)

Decreased 5‐HT(1A) binding in mild Alzheimer's disease—A positron emission tomography study
por: Mattsson, Patrik, et al.
Publicado: (2022)

Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update
por: Farid, Karim, et al.
Publicado: (2017)

Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer’s Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography
por: Willuweit, Antje, et al.
Publicado: (2021)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Amyloid deposition in semantic dementia: a positron emission tomography study
por: Brown, Eric E., et al.
Publicado: (2016)

Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice
por: Franceschi, Ana M., et al.
Publicado: (2022)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018)

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography
por: Tripathi, Shailendra Mohan, et al.
Publicado: (2021)

Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
por: Guix, Francesc X, et al.
Publicado: (2017)

Effect of cognitive reserve on amnestic mild cognitive impairment due to Alzheimer’s disease defined by fluorodeoxyglucose-positron emission tomography
por: Kato, Takashi, et al.
Publicado: (2022)

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria
por: Major, Catherine K, et al.
Publicado: (2021)

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
por: Witte, Michael M., et al.
Publicado: (2015)

Can hippocampal subfield measures supply information that could be used to improve the diagnosis of Alzheimer’s disease?
por: Kannappan, Balaji, et al.
Publicado: (2022)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity
por: Chun, Min Young, et al.
Publicado: (2023)

Differential impact of body mass index and leptin on baseline and longitudinal positron emission tomography measurements of the cerebral metabolic rate for glucose in amnestic mild cognitive impairment
por: Weise, Christopher M., et al.
Publicado: (2022)

Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation
por: Price, Julie C, et al.
Publicado: (2012)

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan
por: Itani, Malak, et al.
Publicado: (2017)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Neural Correlates of Autobiographical Memory: Evidence From a Positron Emission Tomography Study in Patients With Mild Cognitive Impairment and Alzheimer's Disease
por: Frankenberg, Claudia, et al.
Publicado: (2021)

Regional Associations of Cortical Superficial Siderosis and β-Amyloid-Positron-Emission-Tomography Positivity in Patients With Cerebral Amyloid Angiopathy
por: Finze, Anika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dbb15p5tkfpfjc5ioko9gvtjvh